Quarterly revenue of $887 million, at the high end of guidance Quarterly GAAP net income of $23 million and net income per share of $0.33 Quarterly Adjusted EBITDA of $228 million and Non-GAAP net earnings per diluted share of $1.53, exceeding the high-end of guidance ANDOVER, Mass., Aug. Read more
NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms. Bruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional characterization. STRASBOURG, France–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today... Read more
SINGAPORE, Aug. 05, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that Precision Health Research, Singapore (PRECISE) has chosen the Revio HiFi sequencing system for its Long-Read Sequencing Flagship Project. This initiative aims to generate the largest long-read sequencing dataset in Southeast Asia, marking a significant... Read more
Bruker Announces Date and Time of Second Quarter 2024 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the... Read more
Revenue of $2.2 billion , up 26% on a reported basis and 9% organically Earnings per share of $0.80 , up 78%; $1.09 on an adjusted basis, up 11% Raising full-year revenue guidance to $8.55 billion , up approximately 16%, with organic revenue growth of 5% to 6%, up from 4% to 6% Increasing full-year Read more